Tuberculosis vaccine H1IC - Valneva/AJ Vaccines

Drug Profile

Tuberculosis vaccine H1IC - Valneva/AJ Vaccines

Alternative Names: Adjuvanted TB subunit vaccine H1IC - Valneva/AJ Vaccines; Ag85B-ESAT-6-IC31; H1/IC31 vaccine; H1: IC31; H1IC

Latest Information Update: 18 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intercell; Statens Serum Institut
  • Developer AJ Vaccines; Statens Serum Institut; Valneva
  • Class Adjuvants; Antituberculars; Recombinant fusion proteins; Subunit vaccines; Synthetic vaccines; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Tuberculosis

Most Recent Events

  • 16 Jan 2017 Statens Serum Institut sold its vaccine production business to AJ Vaccines
  • 08 Jul 2016 Phase-II clinical trials in Tuberculosis (Prevention) in Tanzania, South Africa (IM) (Aeras pipeline, July 2016)
  • 10 Dec 2014 Phase II development is ongoing South Africa and Tanzania
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top